Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced the issuance of U.S. Patent #12,601,803, titled “System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain.” The patent protects the company’s machine learning platform for analyzing magnetic resonance spectroscopy (MRS) data to identify biomarkers associated with chronic low back pain.
The patented technology underpins Aclarion’s cloud-based Nociscan platform, which converts complex MRS spectral data into clinically actionable insights. By leveraging AI, the platform automates biomarker identification, accelerates report generation, and reduces manual quality reviews. This advancement is expected to enable scalable deployment and improve gross margins, as automated processes lower operational costs.
“This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice,” said Brent Ness, CEO of Aclarion. “By combining proprietary signal processing with machine learning, we are building a scalable and defensible approach to evaluating pain that has the potential to redefine how spine conditions are assessed while enabling highly efficient scaling and strong gross margin expansion.”
The patent covers machine learning models that extract quantitative biomarkers from MRS data to generate standardized classifications for pain-related conditions. It also includes AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids or spectral artifacts. This capability ensures consistent, reproducible outputs across different imaging systems and sites, a key step toward broader clinical adoption.
Aclarion’s intellectual property portfolio now includes 64 issued and pending patents worldwide. The company is focusing on the chronic low back pain market, which affects approximately 266 million people globally. Clinical data shows up to a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools.
For more information about Aclarion and Nociscan, visit the company’s website and newsroom. The patent can be accessed here.
